Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007340
Chunk: 15

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 15
---
 preference shares that we are authorized to issue, as the concept of authorized capital is no longer applicable
under the provisions of the Companies Act. There are no conversion rights, redemption provisions or sinking fund provisions relating to
any Ordinary Shares.

We are not permitted under
English law to hold our own Ordinary Shares unless they are repurchased by us and held in treasury. We do not currently hold any of our
own Ordinary Shares.

History of Share Capital

Since January 1, 2022, our
issued share capital has changed as provided below.

On March 22, 2022, we issued
one Ordinary Share upon the exercise of one warrant issued in February 2019 to a certain institutional investor at an exercise price of
£200 per share.

On
May 3, 2022, we issued 1,250 Ordinary Shares to be purchased under the Biodexa Pharmaceuticals Share Incentive Plan, or the Share Incentive
Plan, at £0.02 per share to the trust of the Share Incentive Plan.

On
August 3, 2022, we issued warrants to purchase 16,666 Ordinary Shares to a certain institutional investor at an exercise price of £2.70
per share.

On
September 26, 2022, we effected a ratio change to the Depositary Shares, pursuant to which the ratio of Ordinary Shares to Depositary
Shares was changed such that one Depositary Share represented 25 Ordinary Shares. Our Ordinary Shares were not affected by this change
and no fractional Depositary Shares were issued.

On
December 16, 2022, we sold to an institutional investor 492,400 Ordinary Shares represented by 49 Depositary Shares in a registered direct
offering at $8,000.00 per Depositary Share, resulting in gross proceeds of approximately $0.4 million.

| 15 |

On February 15, 2023, we completed the closing of a private placement, or the February Private Placement, pursuant to which we sold to certain institutional investors (1) 3,250,000 Ordinary Shares represented by 325 Depositary Shares at $4,640.00 per Depositary Share, (2) 12,931,020 Ordinary Shares represented by 1,293 Depositary Shares, issuable upon the exercise of Series A warrants, or Series A Warrants, issued in the February Private Placement at an exercise price of $5,360.00 per warrant, (3) 19,396